Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$24.84
+0.0%
$23.23
$19.69
$28.35
$4.25B0.81.73 million shs1.05 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$241.00
-0.2%
$239.25
$96.09
$260.19
$12.40B0.61.12 million shs461,964 shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.53
-0.3%
$13.46
$5.69
$13.60
$3.55B1.542.42 million shs3.82 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$10.08
-0.2%
$10.60
$9.23
$28.43
$1.40B0.513.93 million shs2.54 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%-2.97%+4.72%+13.11%+6.75%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%+4.78%+1.55%+29.60%+126.59%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%0.00%+0.37%+19.29%+34.08%
Perrigo Company plc stock logo
PRGO
Perrigo
0.00%-6.05%+4.26%-14.71%-64.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$24.84
+0.0%
$23.23
$19.69
$28.35
$4.25B0.81.73 million shs1.05 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$241.00
-0.2%
$239.25
$96.09
$260.19
$12.40B0.61.12 million shs461,964 shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.53
-0.3%
$13.46
$5.69
$13.60
$3.55B1.542.42 million shs3.82 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$10.08
-0.2%
$10.60
$9.23
$28.43
$1.40B0.513.93 million shs2.54 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%-2.97%+4.72%+13.11%+6.75%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%+4.78%+1.55%+29.60%+126.59%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%0.00%+0.37%+19.29%+34.08%
Perrigo Company plc stock logo
PRGO
Perrigo
0.00%-6.05%+4.26%-14.71%-64.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.67
Moderate Buy$33.1733.52% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.91
Moderate Buy$261.488.50% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-15.71% Downside
Perrigo Company plc stock logo
PRGO
Perrigo
2.00
Hold$19.3391.86% Upside

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Perrigo Company plc stock logo
PRGO
Perrigo
UpgradeSell (E+)Sell (D-)
7/21/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Boost Price TargetOutperform$34.00 ➝ $36.00
7/21/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Boost Price TargetHold$24.00 ➝ $25.00
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Initiated CoverageOutperform$310.00
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
DowngradeHoldStrong Sell
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeStrong-Buy
7/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingSell (D-)
7/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/13/2026
Organon & Co. stock logo
OGN
Organon & Co.
UpgradeHold (C-)Hold (C)
7/8/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/7/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$302.00 ➝ $304.00
(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B3.97$0.89 per share28.00$7.25 per share3.43
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M19.42N/AN/A$1.75 per share137.71
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.57$5.78 per share2.34$2.89 per share4.68
Perrigo Company plc stock logo
PRGO
Perrigo
$4.25B0.33$5.28 per share1.91$21.33 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2011.2925.8817.2234.30%9.61%7.07%8/4/2026 (Confirmed)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A59.36N/A-26.59%-267.16%-28.53%8/10/2026 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.9314.543.931.253.99%99.95%6.22%8/4/2026 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$1.43B-$13.10N/A4.201.20-43.50%9.96%3.90%8/5/2026 (Estimated)

Latest OGN, PRGO, ACAD, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8938N/AN/AN/A$220.94 millionN/A
8/5/2026Q2 2026
Perrigo Company plc stock logo
PRGO
Perrigo
$0.39N/AN/AN/A$1.01 billionN/A
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.06N/AN/AN/A$295.51 millionN/A
8/4/2026Q2 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.87N/AN/AN/A$1.57 billionN/A
5/6/2026Q1 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.04$0.02-$0.02$0.02$280.25 million$268.10 million
5/6/2026Q1 2026
Perrigo Company plc stock logo
PRGO
Perrigo
$0.39$0.43+$0.04-$2.87$1.04 billion$841.80 million
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
4/30/2026Q1 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.59%N/A8.60%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.1611.51%+5.21%N/A 23 Years

Latest OGN, PRGO, ACAD, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.2910.52%5/29/20265/29/20266/16/2026
4/30/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.6%5/11/20265/11/20266/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.59
3.48
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Organon & Co. stock logo
OGN
Organon & Co.
9.47
1.97
1.42
Perrigo Company plc stock logo
PRGO
Perrigo
1.45
2.72
1.59

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510171.24 million126.37 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,100138.37 million137.82 millionOptionable

Recent News About These Companies

Perrigo Stock Dividends | NYSE:PRGO | Benzinga
Perrigo edges higher amid renewed takeover speculation
Perrigo Announces Leadership Transition

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$24.84 +0.01 (+0.04%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$24.84 0.00 (0.00%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$241.00 -0.53 (-0.22%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$235.10 -5.90 (-2.45%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.52 -0.04 (-0.26%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$13.52 -0.01 (-0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Perrigo stock logo

Perrigo NYSE:PRGO

$10.08 -0.02 (-0.23%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$10.09 +0.01 (+0.08%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.